Souhaitez-vous accéder aux communiqués récents ?

The Nextech EDGE 2026 user conference spotlights the company's new AI assistant alongside advancements in data insights, patient experience, and payments.

Knoxville, TN, March 12, 2026 (GLOBE NEWSWIRE) -- LivTech, a leading provider of comprehensive healthcare tech solutions specifically designed for long-term care, today announced the expansion of...

Atavistik Bio closed a $40 million Series B extension for the advancement of its pipeline, bringing total round proceeds to $160 million.

Knoxville, TN, March 03, 2026 (GLOBE NEWSWIRE) -- LivTech, a leading provider of comprehensive healthcare tech solutions specifically designed for senior care, today announced a significant...

Tampa, Fla., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Nextech, an award-winning technology partner for specialty practices and med spas, announced today it has been recognized in the 2026 Best in KLAS®...

Tampa, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Specialty-specific clinical documentation requires more than a generic, automated note taker to truly improve the charting process. Today, Nextech – an...

Dublin, Jan. 23, 2026 (GLOBE NEWSWIRE) -- The "Ophthalmology EMR Software Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Ophthalmology EMR Software...

Delray Beach, FL, Jan. 14, 2026 (GLOBE NEWSWIRE) -- According to MarketsandMarkets™, the global Metaverse Market size is expected to grow from USD 83.9 Billion in 2023 to USD 1,303.4 Billion by 2030...

Proceeds will support the advancement of Atavistik Bio’s oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT) and the JAK2 V617F mutant-selective inhibitor program...

Atavistik Bio to present discovery of JAK2 V617F mutant-selective allosteric Inhibitors for the treatment of myeloproliferative neoplasms at ASH 2025.